MIRNEXT

Mirnext, a biomedical company, focuses on the discovery, validation, and commercialization of miRNAs as novel biomarkers for cardiovascular disease. Its multiple circulating miRNAs act as informative markers for the diagnosis of heart failure, coronary artery disease, and myocardial infarction, as well as used to predict cardiovascular risk, such as mortality and hospitalization. Mirnext also develops multi-marker tests to improve diagnostic routine and clinical management of patients entering the clinic with symptoms of heart failure or coronary artery disease. It has its headquarters in Amsterdam in the Netherlands.